6-甲基-2-甲氧基-3-氨基吡啶 | 186413-79-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 6-甲基-2-甲氧基-3-氨基吡啶
• 中文别名: 2-甲氧基-3-氨基-6-甲基吡啶；3-氨基-2-甲氧基-6-甲基吡啶
• 英文名称: 2-methoxy-6-methylpyridin-3-amine
• 英文别名: 3-Amino-2-methoxy-6-picoline
• CAS: 186413-79-6
• 化学式: C₇H₁₀N₂O
• 分子量: 138.169
• InChiKey: PCFDAJOZHXUBES-UHFFFAOYSA-N

物化性质

• 沸点：
  246.7±35.0 °C(Predicted)
• 密度：
  1.103±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• 海关编码：
  2933399090
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Amino-2-methoxy-6-methylpyridine
Synonyms: 2-Methoxy-6-methylpyridin-3-amine; 5-Amino-6-methoxypicoline

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H315: Causes skin irritation
H335: May cause respiratory irritation
H318: Causes serious eye damage
Avoid breathing dust/fume/gas/mist/vapours/spray
P261:
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Amino-2-methoxy-6-methylpyridine
CAS number: 186413-79-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H10N2O
Molecular weight: 138.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-甲基-2-甲氧基-3-氨基吡啶 在 正丁基锂 、 四甲基乙二胺 、 碘 、 三溴化硼 、 三乙胺 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 反应 15.25h， 生成 N-(4-Iodo-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-2,2-dimethyl-propionamide
  参考文献：
  名称：

  通过金属化-交叉偶联策略合成新的吡啶中间体作为链霉菌素类似物的前体

  摘要：

  从可用的2-氨基-6-氯-3-硝基吡啶开始，描述了链霉菌素类似物的吡啶环C的3-氨基-6-吡啶羧酸衍生物前体的合成。

  DOI：

  10.1002/jhet.5570330670
• 作为产物：
  描述：

  2-氟-6-甲基-3-硝基吡啶 在 10 wt% Pd(OH)2 on carbon 、 甲酸铵 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 mineral oil 为溶剂， 反应 39.0h， 生成 6-甲基-2-甲氧基-3-氨基吡啶
  参考文献：
  名称：

  [EN] COMBINATION OF AN AZETIDINE LPA1 RECEPTOR ANTAGONIST WITH PIRFENIDONE AND/OR NINTEDANIB FOR USE IN THE TREATMENT OF FIBROTIC DISEASES
  [FR] COMBINAISON D'UN ANTAGONISTE DU RÉCEPTEUR LPA1 DE L'AZÉTIDINE AVEC DE LA PIRFÉNIDONE ET/OU DU NINTEDANIB DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT DE MALADIES FIBROTIQUES

  摘要：

  本发明涉及公式（I）中的化合物，其中R1、R2、R3、X和Y如描述中所述，并且它们作为LPA1受体拮抗剂的使用，与一个或多个作为抗纤维化剂的治疗活性成分结合使用；例如特别是匹非尼酮和/或尼替达尼，在预防和/或治疗纤维化疾病方面。该发明还涉及包含公式（I）中的化合物与一个或多个作为抗纤维化剂的治疗活性成分（如匹非尼酮或尼替达尼）结合的药物组合物。

  公开号：

  WO2021110805A1

文献信息

• NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4
  申请人：Perha Pharmaceuticals

  公开号：EP3904354A1

  公开（公告）日：2021-11-03

  The present invention relates to a compound of formula (I) wherein R1 represents a (C1-C6)alkyl group, a spiro(C5-C11)bicyclic ring, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (Ci-C3)alkanediyl group, and R' represents a (C3-C8)cycloalkyl group, a bridged (C6-C10)cycloalkyl group, a (C3-C8)heterocycloalkyl group, or a (C3-C8)heteroaryl group, or a R'-L- group wherein L is a (Ci-C3)alkanediyl group, and R' is a an optionally substituted phenyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits associated with Down syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; diabetes; regulation of folate and methionine metabolism; osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia and infections and for regulating body temperature.

  本发明涉及一种化合物，其化学式为（I），其中R1代表（C1-C6）烷基基团，螺环（C5-C11）双环环，融合苯基团，取代苯基团，R'-L-基团，其中L是一个单键或（Ci-C3）烷二基基团，而R'代表（C3-C8）环烷基团，桥接（C6-C10）环烷基团，（C3-C8）杂环烷基团，或（C3-C8）杂芳基团，或者R'-L-基团，其中L是一个（Ci-C3）烷二基基团，而R'是一个可选择取代的苯基团或其任何药用盐。本发明还涉及包含化合物（I）的组合物，以及制造所述化合物的方法以及其合成中间体。它还涉及所述化合物用作药物，特别是用于治疗和/或预防与唐氏综合症、阿尔茨海默病、痴呆症、tau蛋白病、帕金森病、CDKL5缺陷症、菲兰-麦克德米德综合症、自闭症、糖尿病、叶酸和蛋氨酸代谢调节、骨关节炎、杜兴氏肌营养不良、多种癌症、神经炎症、贫血和感染以及体温调节相关的认知缺陷。
• [EN] HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS
  申请人：INVENTISBIO CO LTD

  公开号：WO2022042630A1

  公开（公告）日：2022-03-03

  Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (A), Formula (II), Formula (III), Formula (IV), or Formula (V), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer (e.g., non-small cell lung cancer) or endometrial cancer.

  本文提供了新颖的化合物，例如具有公式（I），公式（A），公式（II），公式（III），公式（IV）或公式（V）的化合物或其药学上可接受的盐。本文还提供了制备这些化合物的方法和使用这些化合物的方法，例如在癌细胞中抑制KRAS G12D，和/或治疗各种癌症，如胰腺癌，结直肠癌，肺癌（例如非小细胞肺癌）或子宫内膜癌。
• HSP90 INHIBITORS
  申请人：Chen Young K.

  公开号：US20090305998A1

  公开（公告）日：2009-12-10

  The invention relates to HSP90 inhibiting compounds consisting of the formula: wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及抑制HSP90的化合物，其由下式表示：其中变量如定义所述。本发明还涉及包括此类化合物的制药组合物、工具箱和制造物品；用于制备该化合物的方法和中间体；以及使用该化合物的方法。
• THALIDOMIDE ANALOGS
  申请人：Greig Nigel H.

  公开号：US20110245210A1

  公开（公告）日：2011-10-06

  Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

  本文披露了调节肿瘤坏死因子α（TNF-α）活性和血管生成的沙利度胺类似物。在特别披露的实施例中，沙利度胺类似物是同位素硫含量类似物。还披露了使用这些类似物治疗受试者的方法。
• Thalidomide Analogs
  申请人：Greig Nigel H.

  公开号：US20130035363A1

  公开（公告）日：2013-02-07

  Thalidomide analogs that modulate tumor necrosis factor alpha (TNFα) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs.

  本发明揭示了调节肿瘤坏死因子α（TNFα）活性和血管生成的沙利度胺类似物。特别是，本发明揭示的沙利度胺类似物是等构硫含有的类似物。本发明还揭示了使用这些类似物治疗受试者的方法。